Sarepta Therapeutics, Inc. Q4 and Full-Year 2020 Earnings Conference Call Forward Looking Statements

Monday, March 1, 2021 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs, including: our leadership team and its ability to maximize the opportunities in front of us; our revenue guidance for 2021 of $537 million to $547 million; the potential of AMONDYS 45 to treat 8% of the DMD community; the potential of our 3 therapies to treat nearly a third of all patients with DMD; the potential of our RNA-PMO technology to build constructs that can treat more than 80% of all DMD; PPMO's potential to increase cell penetration, improve exposure, exon skipping, and dystrophin production with the goal of profoundly improving outcomes; our confidence in SRP-9001; the expectation that the unique insight we can apply to our next trial for SRP-9001 will give us a much greater probability of success and a competitive edge; the potential of our next trial for SRP-9001 to be the study to support our approval in the U.S. and around the world; the expectation that the PRV transaction will close in Q2; our goal to facilitate rapid patient access of AMONDYS 45 by leveraging our industry-leading knowledge and proven experience; the impact of COVID-19 on our business; expected plans and milestones, including our plans to announce results from our next cohort at 30 mgs/kg in study SRP-5051 in Q2 2021, commence our next trial for SRP-9001 around the middle of 2021 and complete enrollment by the end of 2021, announce results of our first 11 patients in study SRP-9001-103 in Q2 2021, the expectation that the last patient last visit for the full results from part 2 of SRP-9001-102 will occur before the end of 2021, updating the results in SRP-9003-101 in March 2021, commence a pivotal trial for SRP-9003 in 2021, complete toxicology studies for SRP-9004 and SRP-9005, commence a proof-of-concept study using material from NCH for SRP-6004, and have data from the ESSENCE study in 2024.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; the commercial launch for AMONDYS 45 in the U.S. may not be successful for various reasons, including the actual market size and drug supply needed may not be consistent with the company's expectations, the degree to which AMONDYS 45 is accepted by patients and prescribed by physicians, manufacturing limitations, and competitive, reimbursement and regulatory conditions; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; leadership transitions can be inherently difficult to manage and may cause uncertainty or a disruption to our business or may increase the likelihood of turnover in other key officers and employees; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC), as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.